A randomized, double-blind study to assess the optimal duration of doxycycline treatment for human brucellosis

Clinical Infectious Diseases

Volumn 39, Issue 12, 2004, Pages 1776-1782

  Solera, Javier ^a   Geijo, Paloma ^b   Largo, Jose ^c   Rodriguez Zapata, Manuel ^e   Gijón, Julio ^f   Martinez Alfaro, Elisa ^a   Navarro, Elena ^a   Macia, Miguel Angel ^d  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b HOSPITAL VIRGEN DE LA LUZ   (Spain)

^c HOSPITAL VIRGEN DE LA SALUD   (Spain)

^d Junta de Castilla La Mancha   (Spain)

^e HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^f Servicio de Aparato Digestivo   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GENTAMICIN;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRUCELLA; BRUCELLOSIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PHOTOTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BRUCELLOSIS; DOUBLE-BLIND METHOD; DOXYCYCLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 10644225945     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/426024     Document Type: Article

References (20)

1. Food and Agriculture Organization, World Health Organization. Joint FAO-WHO expert committee on brucellosis. World Health Organ Tech Rep Ser 1986; 740:1-132.
2. Solera J, Martínez-Alfaro E, Espinosa E. Recognition and optimum treatment of brucellosis. Drugs 1997; 53:245-56.
3. Young EJ. Brucella species. In: Yu VL, Merigan TC Jr, Barriere SL, eds. Antimicrobial therapy and vaccines. Baltimore: Williams & Wilkins, 1999:71-89.
4. Acocella G, Bertrand A, Beytout J, et al. Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. J Antimicrob Chemother 1989; 23:433-9.
5. Montejo JM, Alberola I, Gonzalez-Zarate P, et al. Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. Clin Infect Dis 1993; 16:671-6.
6. Solera J, Espinosa A, Martínez-Alfaro E, et al. Treatment of human brucellosis with doxycycline and gentamicin. Antimicrob Agents Chemother 1997; 41:80-4.
7. Alton GG, Jones LM, Piles DE. Laboratory techniques in brucellosis. Geneva: World Health Organization, 1975.
8. Solera J, Medrano F, Rodríguez M, Geijo P, Paulino J. Ensayo terapeutico comparativo y multicentrico de rifampicina y doxiciclina frente a estreptomicina y doxiciclina en la brucelosis humana. Med Clin (Barc) 1991; 96:649-53.
9. De Leenheer AP, Nelis HJ. Doxycycline determination in human serum and urine by high-performance liquid chromatography. J Pharm Sci 1979; 68:999-1002.
10. Fleiss JL. Statistical methods for rates and proportions. 2d ed. New York: John Wiley & Sons, 1981:260.
11. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35:1-39.
12. Cox DR. Regression models and life-tables. J R Stat Soc 1972; 34: 187-220.
13. Ariza J, Corredoira J, Pallares R, et al. Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis 1995; 20:1241-9.
14. Solera J, Martinez-Alfaro E, Espinosa A, Castillejos ML, Geijo P, Rodriguez-Zapata M. Multivariate model for predicting relapse in human brucellosis. J Infect 1998; 36:85-92.
15. Lubani MM, Dubin KI, Sharda DC, et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J 1989; 8: 75-8.
16. Abramson O, Abu-Rashid M, Gorodischer R, Yagupsky P. Failure of short antimicrobial treatments for human brucellosis. Antimicrob Agents Chemother 1997; 41:1621-2.
17. Ariza J, Gudiol F, Pallares R, et al. Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin: a randomized, double-blind study. Ann Intern Med 1992; 117:25-30.
18. Ariza J, Gudiol F, Pallares R, Rufi G, Fernandez-Viladrich P. Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis. Antimicrob Agents Chemother 1985; 28:548-51.
19. Ariza J, Gudiol F, Pallares R, Rufi G, Fernandez-Viladrich P. Comparative trial of co-trimoxazole versus tetracycline-streptomycin in treating human brucellosis. J Infect Dis 1985; 152:1358-9.
20. Solera J, Rodriguez-Zapata M, Geijo P, et al. Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. Antimicrob Agents Chemother 1995; 39: 2061-7.